Research programme: integrin antagonists - Celltech
Latest Information Update: 21 Sep 2007
At a glance
- Originator Celltech Group
- Class
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases; Multiple sclerosis; Postmenopausal osteoporosis
Most Recent Events
- 31 Jul 2007 Discontinued - Preclinical for Asthma in United Kingdom (PO)
- 31 Jul 2007 Discontinued - Preclinical for Inflammatory bowel disease in United Kingdom (unspecified route)
- 31 Jul 2007 Discontinued - Preclinical for Multiple sclerosis in United Kingdom (PO)